Ranbaxy Attacks Recall Demand In Glass Particles Action

Law360, New York (February 20, 2013, 2:55 PM EST) -- Ranbaxy Laboratories Ltd. in New Jersey federal court Tuesday attacked a proposed class action targeting its generic version of Lipitor, questioning the honesty of patients allegedly harmed by pills potentially tainted with glass and saying a court-ordered larger recall would usurp regulators' authority.

In its brief opposing a preliminary injunction, the Indian drugmaker cast doubt on the reliability of four individuals who say they suffered harmful side effects, saying three of the patients reported gastrointestinal issues that are common side effects of cholesterol-lowering medicine atorvastatin. As...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.